We are live on ! Find out more
PRTK

Paratek Pharmaceuticals, Inc.

Delisted

PRTK was delisted on the 20th of September, 2023.

62 hedge funds and large institutions have $213M invested in Paratek Pharmaceuticals, Inc. in 2016 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 18 increasing their positions, 15 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

20% more repeat investments, than reductions

Existing positions increased: 18 | Existing positions reduced: 15

0% more funds holding

Funds holding: 6262 (0)

0% more funds holding in top 10

Funds holding in top 10: 33 (0)

0% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 6

18% less capital invested

Capital invested by funds: $259M → $213M (-$45.8M)

Holders
62
Holders Change
Holders Change %
0%
% of All Funds
1.65%
Holding in Top 10
3
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.08%
New
6
Increased
18
Reduced
15
Closed
6
Calls
$282K
Puts
Net Calls
+$282K
Net Calls Change
+$282K
Name Holding Trade Value Shares
Change
Change in
Stake
Fidelity Investments
1
Fidelity Investments
Massachusetts
$39.6M -$441K -28,859 -1%
OFM
2
Omega Fund Management
Massachusetts
$32.4M
BG
3
Baupost Group
Massachusetts
$23.4M
A
4
Abingworth
United Kingdom
$19.7M
TCM
5
Tekla Capital Management
Massachusetts
$11.6M
AC
6
Aisling Capital
New York
$10.4M
BC
7
Broadfin Capital
New York
$8.04M -$15 -1 -0%
FIG
8
Fortress Investment Group
New York
$6.58M +$6.63M +433,804 New
BBHC
9
Brown Brothers Harriman & Co
New York
$5.58M
Vanguard Group
10
Vanguard Group
Pennsylvania
$5.52M +$195K +12,777 +4%
GIM
11
Granahan Investment Management
Massachusetts
$4.87M -$119K -7,749 -2%
BFA
12
BlackRock Fund Advisors
California
$4.82M -$218K -14,254 -4%
GPP
13
Great Point Partners
Connecticut
$4.63M -$765K -50,000 -14%
GAI
14
General American Investors
New York
$4.2M
RSCM
15
Rock Springs Capital Management
Maryland
$3.38M +$2.94M +192,173 +623%
RAM
16
Roumell Asset Management
Maryland
$3.29M +$269K +17,573 +9%
JP Morgan Chase
17
JP Morgan Chase
New York
$3.29M
SM
18
Sabby Management
Florida
$2.92M +$1.07M +69,709 +57%
State Street
19
State Street
Massachusetts
$2.43M +$223K +14,600 +10%
Northern Trust
20
Northern Trust
Illinois
$2.09M +$48.8K +3,193 +2%
BIT
21
BlackRock Institutional Trust
California
$1.97M -$18.8K -1,228 -0.9%
NMC
22
NEA Management Company
Maryland
$1.9M
LOAMU
23
Lombard Odier Asset Management (USA)
New York
$1.36M -$793K -51,836 -37%
Renaissance Technologies
24
Renaissance Technologies
New York
$1.19M -$80.3K -5,249 -6%
OPPM
25
Opus Point Partners Management
New York
$683K -$229K -15,000 -25%

PRTK Hedge Fund Activity: Q1 2016 in Review

62 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in Paratek Pharmaceuticals, Inc. (PRTK) for Q1 2016, worth a combined $213M — down 18% from $259M a quarter earlier.

Fund positioning in PRTK was balanced in Q1 2016: 6 funds opened new positions, 6 closed out, 18 added to existing stakes and 15 trimmed.

The largest buyer was Fortress Investment Group, opening a new position worth an estimated $6.63M. The largest seller was Omega Advisors, exiting entirely with an estimated $2.25M sold.

  • 62 institutional investors held Paratek Pharmaceuticals, Inc. (PRTK) as of Q1 2016, unchanged from Q4 2015.
  • Funds reported $213M of Paratek Pharmaceuticals, Inc. stock for Q1 2016, down 18% quarter-over-quarter.
  • 6 funds opened new Paratek Pharmaceuticals, Inc. positions in Q1 2016 and 6 closed out, a net change of 0 holders.
  • The largest Paratek Pharmaceuticals, Inc. buyer in Q1 2016 was Fortress Investment Group, an estimated $6.63M added.
  • The largest Paratek Pharmaceuticals, Inc. seller in Q1 2016 was Omega Advisors, an estimated $2.25M sold.

Based on aggregated 13F filings for Q1 2016.